Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ALLO-501A |
Synonyms | |
Therapy Description |
ALLO-501A are allogenic CD52 negative T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, a tumor cell surface protein, which potentially results in tumor cell lysis via binding to CD19-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ALLO-501A | ALLO 501A|ALLO501A|Allogeneic Anti-CD19 CAR T-cells ALLO-501A | ALLO-501A are allogenic CD52 negative T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, a tumor cell surface protein, which potentially results in tumor cell lysis via binding to CD19-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05714345 | Phase II | Cyclophosphamide + Fludarabine ALLO-647 + Cyclophosphamide + Fludarabine ALLO-501A | Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPAND) | Recruiting | USA | BEL | AUT | 0 |
NCT04416984 | Phase Ib/II | ALLO-501A ALLO-647 + Cyclophosphamide + Fludarabine | Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA-2) (ALPHA-2) | Recruiting | USA | ITA | ESP | CAN | AUS | 0 |